Anteris Technologies Ltd (AVR)

AVR Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

AVR's Principal Activity is the sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Mr Stephen (Steve) Denaro	Company Secretary,Non-Executive Director	Oct 2018	Mr Stephen (Steve) Denaro Company Secretary,Non-Executive Director Mr Denaro has more than 30 years of senior level and Board level experience across publicly listed companies; serving as Chief Financial Officer, Company Secretary and Director. He has experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). He also chairs the Risk Management Committee.
Dr Wenyi Gu	Non-Executive Director	Oct 2018	Dr Wenyi Gu Non-Executive Director Dr Gu works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before he was into nano medicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). His research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd. He is also a member of Risk Management Committee.
Mr Wayne Paterson	Managing Director,Chief Executive Officer	Feb 2016	Mr Wayne Paterson Managing Director,Chief Executive Officer Mr Paterson has held senior positions in multi national pharmaceutical companies during the past 25 years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, he served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He held as a director in Cepheid Inc from April 2015 to November 2016.
Mr John Seaberg	Non-Executive Director,Non-Executive Chairman	Oct 2014	Mr John Seaberg Non-Executive Director,Non-Executive Chairman Mr Seaberg served as Chairman of the Board of Synovis Inc, a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products from 2008 until its sale to Baxter in 2012. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc., a venture capital backed company commercializing technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, he served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, he was co-founder of ACIST Medical and served as its first President and CEO. He is also a member of Member of the Risk Management Committee.
Matthew McDonnell	Chief Financial Officer	N/A
Kiran Bhirangi	Chief Medical Officer	N/A
David St Denis	Chief Operating Officer	N/A
Martha Engel	General Counsel	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
10/12/20	Wayne Paterson	Expiry	1,000	$3.80	$3,800	Options expired
10/12/20	John Seaberg	Expiry	1,000	$3.80	$3,800	Options expired
20/03/20	Stephen (Steve) Denaro	Issued	25,000	$3.50	$87,500	Issue of options
20/03/20	Wayne Paterson	Issued	350,000	$3.50	$1,225,000	Issue of options
20/03/20	John Seaberg	Issued	60,000	$3.50	$210,000	Issue of options
18/12/18	John Seaberg	Issued	700,000	$0.08	$56,000	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.08	$3,774,278	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.061	$3,836,732	Rights issue
18/12/18	Yanheng Wu	Issued	47,178,461	$0.061	$2,877,886	Rights issue
18/12/18	Lishan Zhang	Issued	62,897,248	$0.08	$5,031,781	Rights issue
28/06/18	John Seaberg	Issued	166,667	$0.30	$50,000	Placement
08/06/18	Catherine (Kate) Costello	Issued	418,817	$0.124	$51,869	Issue of options
08/06/18	Wayne Paterson	Issued	1,435,630	$0.124	$177,798	Issue of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Wayne Paterson	10/12/2020	916,667	N/A	403,248	N/A
John Seaberg	10/12/2020	885,703	N/A	67,000	N/A
Stephen (Steve) Denaro	20/03/2020	0	N/A	25,000	N/A
Wenyi Gu	N/A	N/A	N/A	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
Constellation Intl Holdings Limited	730,192	12.35%
HSBC Custody Nominees (Australia) Limited A/C 2	652,219	11.04%
Constellation Immunotherapy Limited	402,093	6.80%
National Nominees Limited <Db A/C>	373,228	6.31%
HSBC Custody Nominees (Australia) Limited Gsco Eca	290,293	4.91%
Star Bright Holding Limited	173,680	2.94%
Merrill Lynch (Australia) Nominees Pty Limited <Mlpro A/C>	169,733	2.87%
J P Morgan Nominees Australia Pty Limited	87,768	1.48%
Citicorp Nominees Pty Limited	84,369	1.43%
Mr Patrick Chew	73,670	1.25%
Dr Abdul Ahad Khan	36,895	0.62%
Mr Daniel Bernard Clough	33,584	0.57%
Through2 Investments Pty Ltd <Through2 Super Fund A/C>	33,000	0.56%
Mr Roger Anthony Pierce	32,673	0.55%
Bulldog Shale Pty Ltd <Bulldog Shale S Fund A/C>	30,000	0.51%
Carron Services Limited	28,572	0.48%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle	23,527	0.40%
Mr Athanasios Farmakis	23,000	0.39%
Zcsf Nominees Pty Ltd <Zoeller Superfund A/C>	20,505	0.35%
Mr Dale Anthony Reed	20,000	0.34%
Appwam Pty Ltd	20,000	0.34%
Mrs Janet Louise Bowtell and Mr Gary Owen Bowtell <Bowtell Super Fund A/C>	20,000	0.34%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$4.90	30 June

AVR Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.